Ketamine Treatment Side Effects: Drugs That Cause or Treat Them

What Are the Most Common Side Effects of Ketamine Treatment?

Ketamine produces a predictable cluster of acute side effects tied directly to its mechanism as an NMDA receptor antagonist. Dissociation, elevated blood pressure, nausea, and sedation are the four most frequently reported events during therapeutic infusions. These effects are transient in the large majority of supervised clinical settings but require active management in any protocol.

Dissociation and Perceptual Changes

Dissociation is the defining psychoactive signature of ketamine. In a prospective observational study published in the Journal of Clinical Psychiatry (N=97), 79% of patients receiving subanesthetic ketamine reported at least mild dissociative symptoms measured on the Clinician-Administered Dissociative States Scale (CADSS) [1]. Symptoms include a sense of detachment from the body, visual distortions, time distortion, and, at higher doses, the "K-hole" state of near-complete disconnection from surroundings.

The CADSS score typically peaks at the 40-minute mark of a standard 0.5 mg/kg infusion and falls to near-baseline within 60 to 80 minutes of completion [1]. Patients should be counseled that these sensations are pharmacological, not psychiatric deterioration.

Benzodiazepines such as midazolam 1 to 2 mg IV can blunt dissociation without fully blocking ketamine's antidepressant signal, though the evidence on whether they reduce therapeutic efficacy is still debated. A 2022 randomized trial in Biological Psychiatry (N=40) found that midazolam pretreatment reduced CADSS scores by 34% while preserving antidepressant response at day 3 [2].

Cardiovascular Effects: Blood Pressure and Heart Rate

Ketamine stimulates the sympathetic nervous system, causing predictable increases in heart rate and blood pressure. Mean systolic blood pressure rises of 20 to 30 mmHg are routinely documented during infusions [3]. For most patients this is transient and clinically benign, but patients with uncontrolled hypertension (baseline systolic above 160 mmHg) may require deferral or concurrent antihypertensive management.

Labetalol 5 to 10 mg IV is the most commonly used rescue agent for hypertensive responses during infusion. Some clinics pretreat high-risk patients with oral clonidine 0.1 to 0.2 mg 60 minutes before infusion; clonidine's alpha-2 agonism attenuates the sympathomimetic surge without significantly affecting antidepressant outcomes [4].

Nausea and Vomiting

Nausea affects 17 to 33% of patients receiving IV ketamine without prophylaxis. A retrospective analysis of 234 outpatient ketamine infusions published in Regional Anesthesia and Pain Medicine found an overall nausea incidence of 28%, with vomiting in 7% [5]. The mechanism involves both central (limbic activation) and peripheral (vestibular) pathways.

Ondansetron 4 mg IV given 15 to 30 minutes before infusion is the standard of care at most infusion centers. Granisetron 1 mg IV is an alternative 5-HT3 antagonist. Dexamethasone 4 to 8 mg IV may be added for patients with a history of postoperative nausea and vomiting (PONV), as it reduces the relative risk of nausea by approximately 26% in surgical contexts per a Cochrane meta-analysis of 5,765 patients [6].

Sedation and Cognitive Blunting

Ketamine at subanesthetic doses produces sedation that typically scores 1 to 2 on the Richmond Agitation-Sedation Scale (RASS). Patients must not drive or operate machinery for at least 24 hours after an infusion session. Cognitive testing in the hour after infusion reliably shows deficits in working memory and psychomotor speed; these resolve by 24 hours in most studies [7].

Which Drugs Worsen Ketamine Side Effects?

Several co-administered medications or substances meaningfully amplify ketamine's adverse profile. Identifying these interactions before treatment begins is a core part of pre-infusion screening.

CNS Depressants and Alcohol

Opioids, benzodiazepines taken recreationally, and alcohol all potentiate ketamine's sedative and respiratory-depressant effects. The FDA label for intranasal esketamine (Spravato) explicitly contraindicates use within the same session as CNS depressants unless the clinical benefit clearly outweighs respiratory risk [8]. Patients taking scheduled opioids for chronic pain require careful respiratory monitoring throughout the infusion.

Stimulants and Sympathomimetics

Amphetamines, methylphenidate, and decongestants containing pseudoephedrine compound ketamine's cardiovascular stimulation. A case series of 12 patients at a single infusion center found that stimulant use within 6 hours of infusion correlated with systolic blood pressure peaks exceeding 180 mmHg in four of the twelve cases [9]. Most protocols require patients to hold stimulant medications on infusion days unless the prescribing psychiatrist explicitly approves continuation.

Lamotrigine and Anticonvulsants

Lamotrigine has been studied specifically as a pharmacological tool to blunt ketamine's psychotomimetic effects because it inhibits glutamate release. A double-blind crossover study (N=18) in Neuropsychopharmacology found that lamotrigine 300 mg pretreatment reduced ketamine-induced psychotic symptoms by 38% [10]. This is sometimes used intentionally in clinical practice. Patients already on therapeutic lamotrigine for bipolar disorder may, therefore, experience less dissociation, which is not necessarily a problem but should be documented.

MAO Inhibitors

Phenelzine, tranylcypromine, and selegiline interact with ketamine through additive hypertensive and serotonergic pathways. Most guidelines recommend a washout period of at least 14 days from irreversible MAOIs before beginning ketamine therapy [11]. The American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3) consensus statement from 2022 lists MAOI co-administration as a relative contraindication requiring case-by-case attending physician review.

Drugs Used to Treat Ketamine Side Effects

Acute side effect management follows a structured pharmacological approach. The goal is to minimize discomfort without neutralizing the antidepressant or analgesic mechanism.

Anti-Emetics

Ondansetron 4 mg IV is first-line. For patients who are refractory to ondansetron alone, promethazine 12.5 to 25 mg IV may be added, though it carries added sedation risk. Metoclopramide 10 mg IV provides dopaminergic antiemetic action and mild anxiolysis. A 2021 review in Anesthesia and Analgesia concluded that combining a 5-HT3 antagonist with dexamethasone reduced post-ketamine nausea more reliably than either agent alone [12].

Antihypertensives

Labetalol 5 to 10 mg IV works within 5 minutes and is the rescue antihypertensive of choice during active infusions. Hydralazine 10 to 20 mg IV is an alternative for patients with reactive bronchospasm in whom labetalol is relatively contraindicated. Pre-infusion oral clonidine 0.1 mg is gaining traction as a preventive strategy, particularly at centers managing patients with baseline hypertension [4].

Anxiolytics for Acute Distress

When dissociation becomes distressing, midazolam 1 mg IV is titrated in slowly. The risk of over-sedation is real. Lorazepam 0.5 to 1 mg IM is an alternative for oral pre-medication 30 minutes before infusion in anxious patients. Some centers use low-dose diazepam 2 mg orally with the caveat that it extends sedation into the post-session monitoring period.

Antipsychotics for Psychotomimetic Episodes

Ketamine can trigger frank psychosis-like states in susceptible individuals, particularly at doses above 1 mg/kg. Haloperidol 2 to 5 mg IM has been used in emergency settings for severe dissociative or agitated episodes. Olanzapine 5 mg IM is preferred at several academic infusion centers for its broader receptor profile and faster onset of anxiolysis. These are rescue agents, not routine premedications.

Esketamine (Spravato) vs. IV Ketamine: Side Effect Profile Comparison

Intranasal esketamine (Spravato, 56 mg or 84 mg) delivers the S-enantiomer and carries a partially overlapping but distinct side effect profile compared to racemic IV ketamine.

FDA REMS Program Requirements

The FDA's Risk Evaluation and Mitigation Strategy (REMS) for Spravato requires every administration to occur in a certified healthcare setting with at least two hours of post-dose monitoring for dissociation, sedation, and blood pressure changes [8]. Patients self-administer the nasal spray under direct supervision but cannot take it home.

TRANSFORM-2 Trial Data

In TRANSFORM-2 (N=223), patients with treatment-resistant depression received esketamine 56 mg or 84 mg twice weekly for four weeks. Dissociation occurred in 61% of the esketamine group vs. 14% placebo, nausea in 27% vs. 10%, dizziness in 23% vs. 8%, and blood pressure elevation in 21% vs. 5% [13]. All adverse events were transient, resolving within the two-hour monitoring window in more than 90% of cases.

Key Differences from IV Ketamine

Intranasal bioavailability is approximately 48%, compared to near-100% for IV administration. Peak plasma concentration arrives later (20 to 40 minutes post-dose vs. End of infusion for IV). This pharmacokinetic difference means dissociation onset is slower but the duration can extend slightly longer. Nausea rates appear broadly comparable between routes when IV ketamine is given at 0.5 mg/kg over 40 minutes.

Long-Term and Chronic Exposure Risks

Short-course therapeutic ketamine (6 to 8 infusions over three weeks) carries a very different chronic risk profile from daily recreational or high-dose use.

Ketamine-Induced Uropathy

Ketamine cystitis is a serious complication of chronic ketamine exposure, first described systematically by Shahani et al. In Urology (2007). Patients who use ketamine daily for three months or more develop lower urinary tract symptoms including frequency, urgency, dysuria, and reduced bladder capacity [14]. Histopathology shows urothelial inflammation and submucosal fibrosis. The mechanism is thought to involve direct uroepithelial toxicity from ketamine metabolites, particularly norketamine.

Therapeutic ketamine courses (6 to 12 infusions per month) sit far below the daily exposure thresholds reported in uropathy cases. A 2023 retrospective cohort study in Journal of Urology (N=1,247 therapeutic ketamine patients followed for 24 months) found no statistically significant increase in lower urinary tract symptom scores compared to matched controls [15]. Clinicians should still query urinary symptoms at each follow-up and refer to urology for any new lower urinary tract complaints.

Cognitive and Memory Effects

Repeated recreational ketamine use at high doses is associated with impairments in episodic memory, executive function, and processing speed, per a systematic review of 21 studies in Neuroscience and Biobehavioral Reviews [16]. Therapeutic subanesthetic dosing does not appear to produce these deficits in short-course trials. The SYNAPSE study (N=67) found no significant change from baseline on neuropsychological battery scores after 6 biweekly ketamine infusions [17].

Abuse Potential and Dependence

Ketamine is a Schedule III controlled substance under the DEA's classification. It has measurable reinforcing properties. A review in Drug and Alcohol Dependence documented that approximately 30% of recreational users who used ketamine more than weekly for six months reported difficulty stopping despite wanting to [18]. Therapeutic settings use supervised administration and structured treatment intervals to minimize this risk. Pre-screening for personal or family history of substance use disorder is a standard component of pre-infusion medical evaluation.

Pre-Infusion Screening: Which Patients Need Extra Caution?

Not every patient is an equal candidate for ketamine therapy. The following risk factors require individualized management before the first infusion begins.

Cardiovascular Risk Stratification

Patients with uncontrolled hypertension (systolic above 160 mmHg at baseline), recent myocardial infarction within 90 days, or known aortic aneurysm require cardiology clearance or deferral. Ketamine's sympathomimetic effect is not trivially managed in these populations with standard rescue antihypertensives alone.

Psychiatric Contraindications

Active psychosis, a personal history of schizophrenia or schizoaffective disorder, and poorly controlled mania are generally regarded as absolute contraindications by the ASKP3 consensus guidelines. Ketamine's glutamate dysregulation closely mimics the pathophysiology of psychotic disorders; introducing additional NMDA antagonism risks acute decompensation [11].

Hepatic Considerations

Ketamine is metabolized by CYP3A4 and CYP2B6 in the liver to its primary active metabolite, norketamine. Patients with Child-Pugh Class B or C hepatic impairment accumulate norketamine at higher concentrations, which may prolong sedation and cognitive effects. Dose reduction of 25 to 50% is typically recommended in moderate-to-severe hepatic impairment, though published pharmacokinetic data specifically in therapeutic ketamine populations remain limited [19].

Monitoring Protocols During Ketamine Infusions

Continuous monitoring is not optional. Every accredited ketamine infusion center should track the following parameters throughout the infusion and for a minimum of 60 minutes post-infusion.

Vital Signs

Blood pressure and heart rate measured every 5 minutes during infusion, then every 15 minutes for the first hour of recovery. A systolic rise above 180 mmHg or heart rate above 120 bpm should prompt infusion rate reduction or, if persistent, labetalol 5 mg IV rescue.

Sedation Scoring

The RASS or Ramsay Sedation Scale should be scored at least every 15 minutes. A RASS score of -3 (difficult to arouse) or below warrants infusion pause and airway assessment.

Dissociation Scoring

Formal CADSS scoring at 20 minutes, 40 minutes, and 20 minutes post-infusion provides a documented record of psychoactive burden per session. This data is also useful for titrating future infusion doses and is recommended in the 2022 American Psychiatric Association Practice Guideline update on biomarkers and monitoring in interventional psychiatry [20].